PAPER Miller EC, Conley P, Alirezaei M, Wolfova K, Gonzales MM, Tan ZS, Tom SE, Yee LM, Brickman AM, Bello NA

Associations between adverse pregnancy outcomes and cognitive impairment and dementia: a systematic review and meta-analysis.

Lancet Healthy Longev. 2024 Dec;5(12):100660. Epub 2024 Dec 12 PubMed.

PAPER Mekala S, Wu Y, Li YM

Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders.

RSC Med Chem. 2024 Nov 20; Epub 2024 Nov 20 PubMed.

PAPER Tascedda S, Sarti P, Rivi V, Guerrera CS, Platania GA, Santagati M, Caraci F, Blom JM

Advanced AI techniques for classifying Alzheimer's disease and mild cognitive impairment.

Front Aging Neurosci. 2024;16:1488050. Epub 2024 Nov 29 PubMed.

PAPER Zhu F, Yin S, Wang Y, Zhong Y, Ji Q, Wu J

Effects of Probiotics on Neurodegenerative Disease-Related Symptoms and Systemic Inflammation: A Systematic Review.

Int J Gen Med. 2024;17:5941-5958. Epub 2024 Dec 10 PubMed.

PAPER Wyman-Chick KA, Barrett MJ, Miller MJ, Sargent L, Chrenka EA, Kane JP, Crowley SJ, Kuntz JL, Parashos SA, Schousboe JT, Nguyen H, Werner AM, Rossom RC

The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies.

Alzheimers Dement (Amst). 2024;16(4):e70034. Epub 2024 Dec 14 PubMed.

PAPER Cohen JS, Phillips J, Das SR, Olm CA, Radhakrishnan H, Rhodes E, Cousins KA, Xie SX, Nasrallah IM, Yushkevich PA, Wolk DA, Lee EB, Weintraub D, Irwin DJ, McMillan CT

Posterior hippocampal sparing in Lewy body disorders with Alzheimer's copathology: An in vivo MRI study.

Neuroimage Clin. 2024 Dec 7;45:103714. Epub 2024 Dec 7 PubMed.

PAPER Travaglia A, Lal S, Pullagura SR

Advancing ALS research: public-private partnerships to accelerate drug and biomarker development.

Trends Neurosci. 2025 Jan;48(1):1-2. Epub 2024 Nov 21 PubMed.

PAPER Sehlin D, Roshanbin S, Zachrisson O, Ingelsson M, Syvänen S

A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology.

Neurotherapeutics. 2025 Mar;22(2):e00510. Epub 2024 Dec 14 PubMed.

PAPER Rose S, Gergoire A, Pal S, Reader J, Bhaumik A, Slotkin J, Ho E, Nowinski CJ, Persad CC, Maher AC, Weintraub S, Gershon R, Giordani B

Evaluating the factor structure and construct validity of the NIH toolbox in older adults, with a focus on cognitive normalcy and amnestic mild cognitive impairment: considerations for diversity, including insights from persons over 85 years of age and Bl

J Int Neuropsychol Soc. 2024 Dec 16;:1-6. Epub 2024 Dec 16 PubMed.

APP K724M

MUTATIONS APP 25891762 GRCh38/hg38 A T 27264074 GRCh37/hg19 A T Exon 17 Coding Increased Aβ42/Aβ40 ratio and Aβ42 levels in cultured cells.  Unknown, but in one carrier, MRI revealed mild global brain atrophy and enlargement of the ventricles. K724M Alzheimer'

Frank Longo, Stephen Massa on Is It Time to Approve Drugs Based on Amyloid Removal?

COMMENT The Aisen et al. Perspective article argues that robust reduction of amyloid PET signal achieved by Aβ antibody-based therapies should serve as a surrogate biomarker of clinical response for approval of such treatments. The article provides a convincing s

Russell Swerdlow on Is It Time to Approve Drugs Based on Amyloid Removal?

COMMENT It is interesting that the datasets, studies, and arguments presented in this perspective paper bring others to different conclusions, and with an equal degree of conviction. rswerdlow 0

Jae-Hong Lee on Is It Time to Approve Drugs Based on Amyloid Removal?

COMMENT A surrogate marker for clinical outcomes in Alzheimer’s therapeutics has long been regarded as the Holy Grail in the field. It could definitely make new drug development much easier and faster. I agree with the authors of this position paper that, based o

Jae-Hong Lee

Asan Medical Center
Korea, Republic of

Fabien Lanté